Clinical characteristics of healthy controls and patients with HFpEF
| Characteristic | Control (n=18) | HFpEF (n=18) | HF MRT <60 s (n=9) | HF MRT ≥60 s (n=9) |
| Sex (M:F) | 8:10 | 8:10 | 4:5 | 4:5 |
| Age (year) | 70 (7) | 68 (7) | 68 (7) | 69 (7) |
| Height (cm) | 167 (10) | 167 (9) | 167 (8) | 166 (10) |
| Weight (kg) | 75 (12) | 99 (19)* | 100 (15)* | 98 (24)* |
| BMI (kg/m2) | 26 (3) | 35 (6)* | 36 (4)* | 35 (7)* |
| BSA (m2) | 1.85 (0.19) | 2.13 (0.26)* | 2.15 (0.2)* | 2.11 (0.3)* |
| HF pharmacotherapy, n (%) | ||||
| Diuretic | 16 (89) | 7 (78) | 9 (100) | |
| ACEi or ARB | 11 (61) | 4 (44) | 7 (78) | |
| β-blocker | 11 (61) | 4 (44) | 7 (78) | |
| Nitrate | 4 (22) | 1 (11) | 3 (33) | |
| Statin | 8 (44) | 3 (33) | 5 (56) | |
| Aspirin | 6 (33) | 1 (11) | 5 (56) | |
Mean (SD) unless otherwise noted.
*P<0.05 versus control.
ACEi, ACE inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BSA, Body surface area; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; MRT, mean response time.